<author><surname>Stacy</surname> <given-names>M</given-names> </author><title>Medical treatment of Parkinson disease</title><source>Neurol Clin</source><year>2009</year><volume>27</volume><issue>3</issue><fpage>605</fpage><lpage>631</lpage>
<author><surname>Tanner</surname> <given-names>CM</given-names> </author><author><surname>Ross</surname> <given-names>GW</given-names> </author><author><surname>Jewell</surname> <given-names>SA</given-names> </author><title>Occupation and risk of parkinsonism: a multicenter case-control study</title><source>Arch Neurol</source><year>2009</year><volume>66</volume><issue>9</issue><fpage>1106</fpage><lpage>1113</lpage>
<title>US interim projections by age, sex, race, and hispanic origin: 2000&#8211;2050</title>Available from:
<author><surname>Cotzias</surname> <given-names>GC</given-names> </author><author><surname>Papavasiliou</surname> <given-names>PS</given-names> </author><author><surname>Gellene</surname> <given-names>R</given-names> </author><title>Modif ication of Parkinsonism &#8211; chronic treatment with L-dopa</title><source>N Engl J Med</source><year>1969</year><volume>280</volume><issue>7</issue><fpage>337</fpage><lpage>345</lpage>
<author><surname>Lang</surname> <given-names>AE</given-names> </author><author><surname>Lozano</surname> <given-names>AM</given-names> </author><title>Parkinson&#8217;s disease. First of two parts</title><source>N Engl J Med</source><year>1998</year><volume>339</volume><issue>15</issue><fpage>1044</fpage><lpage>1053</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><title>Motor fluctuations and dyskinesia in Parkinson&#8217;s disease</title><source>Parkinsonism Relat Disord</source><year>2001</year><volume>8</volume><issue>2</issue><fpage>101</fpage><lpage>108</lpage>
<author><surname>Fahn</surname> <given-names>S</given-names> </author><author><surname>Oakes</surname> <given-names>D</given-names> </author><author><surname>Shoulson</surname> <given-names>I</given-names> </author><title>Levodopa and the progression of Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2004</year><volume>351</volume><issue>24</issue><fpage>2498</fpage><lpage>2508</lpage>
<author><surname>Fahn</surname> <given-names>S</given-names> </author><title>The spectrum of levodopa-induced dyskinesias</title><source>Ann Neurol</source><year>2000</year><volume>47</volume><issue>Suppl 1</issue><fpage>2</fpage><lpage>11</lpage>
<author><surname>Golbe</surname> <given-names>LI</given-names> </author><title>Young-onset Parkinson&#8217;s disease: a clinical review</title><source>Neurology</source><year>1991</year><volume>41</volume><issue>2 Pt 1</issue><fpage>168</fpage><lpage>173</lpage>
<author><surname>Forno</surname> <given-names>LS</given-names> </author><title>Neuropathology of Parkinson&#8217;s disease</title><source>J Neuropathol Exp Neurol</source><year>1996</year><volume>55</volume><issue>3</issue><fpage>259</fpage><lpage>272</lpage>
<author><surname>Jellinger</surname> <given-names>KA</given-names> </author><title>Post mortem studies in Parkinson&#8217;s disease &#8211; is it possible to detect brain areas for specific symptoms?</title><source>J Neural Transm Suppl</source><year>1999</year><volume>56</volume><fpage>1</fpage><lpage>29</lpage>
<author><surname>Grace</surname> <given-names>AA</given-names> </author><author><surname>Bunney</surname> <given-names>BS</given-names> </author><title>The control of firing pattern in nigral dopamine neurons: single spike firing</title><source>J Neurosci</source><year>1984</year><volume>4</volume><issue>11</issue><fpage>2866</fpage><lpage>2876</lpage>
<author><surname>Grace</surname> <given-names>AA</given-names> </author><title>Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia</title><source>Neuroscience</source><year>1991</year><volume>41</volume><issue>1</issue><fpage>1</fpage><lpage>24</lpage>
<author><surname>Abercrombie</surname> <given-names>ED</given-names> </author><author><surname>Bonatz</surname> <given-names>AE</given-names> </author><author><surname>Zigmond</surname> <given-names>MJ</given-names> </author><title>Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats</title><source>Brain Res</source><year>1990</year><volume>525</volume><issue>1</issue><fpage>36</fpage><lpage>44</lpage>
<author><surname>Schultz</surname> <given-names>W</given-names> </author><title>Predictive reward signal of dopamine neurons</title><source>J Neurophysiol</source><year>1998</year><volume>80</volume><issue>1</issue><fpage>1</fpage><lpage>27</lpage>
<author><surname>Venton</surname> <given-names>BJ</given-names> </author><author><surname>Zhang</surname> <given-names>H</given-names> </author><author><surname>Garris</surname> <given-names>PA</given-names> </author><author><surname>Phillips</surname> <given-names>PE</given-names> </author><author><surname>Sulzer</surname> <given-names>D</given-names> </author><author><surname>Wightman</surname> <given-names>RM</given-names> </author><title>Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing</title><source>J Neurochem</source><year>2003</year><volume>87</volume><issue>5</issue><fpage>1284</fpage><lpage>1295</lpage>
<author><surname>Olanow</surname> <given-names>CW</given-names> </author><author><surname>Obeso</surname> <given-names>JA</given-names> </author><author><surname>Stocchi</surname> <given-names>F</given-names> </author><title>Continuous dopamine-receptor treatment of Parkinson&#8217;s disease: scientific rationale and clinical implications</title><source>Lancet Neurol</source><year>2006</year><volume>5</volume><issue>8</issue><fpage>677</fpage><lpage>687</lpage>
<author><surname>Lewitt</surname> <given-names>PA</given-names> </author><title>Levodopa for the treatment of Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>23</issue><fpage>2468</fpage><lpage>2476</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><author><surname>Woodward</surname> <given-names>WR</given-names> </author><author><surname>Beckner</surname> <given-names>RM</given-names> </author><title>Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients</title><source>Neurology</source><year>1994</year><volume>44</volume><issue>5</issue><fpage>913</fpage><lpage>919</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><title>Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients</title><source>Neurology</source><year>2000</year><volume>55</volume><issue>11 Suppl 4</issue><fpage>S33</fpage><lpage>S37</lpage>
<author><surname>De la Fuente-Fern&#225;ndez</surname> <given-names>R</given-names> </author><author><surname>Sossi</surname> <given-names>V</given-names> </author><author><surname>Huang</surname> <given-names>Z</given-names> </author><title>Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson&#8217;s disease: implications for dyskinesias</title><source>Brain</source><year>2004</year><volume>127</volume><issue>Pt 12</issue><fpage>2747</fpage><lpage>2754</lpage>
<author><surname>Olanow</surname> <given-names>CW</given-names> </author><author><surname>Obeso</surname> <given-names>JA</given-names> </author><title>Preventing levodopa-induced dyskinesias</title><source>Ann Neurol</source><year>2000</year><volume>47</volume><issue>4 Suppl 1</issue><fpage>S167</fpage><lpage>S176</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><author><surname>Carter</surname> <given-names>JH</given-names> </author><author><surname>Lea</surname> <given-names>ES</given-names> </author><author><surname>Woodward</surname> <given-names>WR</given-names> </author><title>Motor fluctuations during continuous levodopa infusions in patients with Parkinson&#8217;s disease</title><source>Mov Disord</source><year>1997</year><volume>12</volume><issue>3</issue><fpage>285</fpage><lpage>292</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Vacca</surname> <given-names>L</given-names> </author><author><surname>Ruggieri</surname> <given-names>S</given-names> </author><author><surname>Olanow</surname> <given-names>CW</given-names> </author><title>Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study</title><source>Arch Neurol</source><year>2005</year><volume>62</volume><issue>6</issue><fpage>905</fpage><lpage>910</lpage>
<author><surname>Antonini</surname> <given-names>A</given-names> </author><author><surname>Isaias</surname> <given-names>IU</given-names> </author><author><surname>Canesi</surname> <given-names>M</given-names> </author><title>Duodenal levodopa infusion for advanced Parkinson&#8217;s disease: 12-month treatment outcome</title><source>Mov Disord</source><year>2007</year><volume>22</volume><issue>8</issue><fpage>1145</fpage><lpage>1149</lpage>
<author><surname>Pearce</surname> <given-names>RK</given-names> </author><author><surname>Banerji</surname> <given-names>T</given-names> </author><author><surname>Jenner</surname> <given-names>P</given-names> </author><author><surname>Marsden</surname> <given-names>CD</given-names> </author><title>De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset</title><source>Mov Disord</source><year>1998</year><volume>13</volume><issue>2</issue><fpage>234</fpage><lpage>241</lpage>
<author><surname>Rascol</surname> <given-names>O</given-names> </author><author><surname>Brooks</surname> <given-names>DJ</given-names> </author><author><surname>Korczyn</surname> <given-names>AD</given-names> </author><author><surname>de Deyn</surname> <given-names>PP</given-names> </author><author><surname>Clarke</surname> <given-names>CE</given-names> </author><author><surname>Lang</surname> <given-names>AE</given-names> </author><title>A five-year study of the incidence of dyskinesia in patients with early Parkinson&#8217;s disease who were treated with ropinirole or levodopa</title><source>N Engl J Med</source><year>2000</year><volume>342</volume><issue>20</issue><fpage>1484</fpage><lpage>1491</lpage>
<author><surname>Olanow</surname> <given-names>CW</given-names> </author><title>The scientific basis for the current treatment of Parkinson&#8217;s disease</title><source>Annu Rev Med</source><year>2004</year><volume>55</volume><fpage>41</fpage><lpage>60</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Rascol</surname> <given-names>O</given-names> </author><author><surname>Kieburtz</surname> <given-names>K</given-names> </author><title>Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study</title><source>Ann Neurol</source><year>2010</year><volume>68</volume><issue>1</issue><fpage>18</fpage><lpage>27</lpage>
<author><surname>Smith</surname> <given-names>LA</given-names> </author><author><surname>Jackson</surname> <given-names>MJ</given-names> </author><author><surname>Al-Barghouthy</surname> <given-names>G</given-names> </author><title>Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates</title><source>Mov Disord</source><year>2005</year><volume>20</volume><issue>3</issue><fpage>306</fpage><lpage>314</lpage>
<author><surname>Suzuki</surname> <given-names>K</given-names> </author><author><surname>Nakazato</surname> <given-names>H</given-names> </author><author><surname>Matsui</surname> <given-names>H</given-names> </author><title>Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population</title><source>Cancer</source><year>2003</year><volume>98</volume><issue>7</issue><fpage>1411</fpage><lpage>1416</lpage>
<author><surname>Tanaka</surname> <given-names>Y</given-names> </author><author><surname>Sasaki</surname> <given-names>M</given-names> </author><author><surname>Shiina</surname> <given-names>H</given-names> </author><title>Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer</title><source>Cancer Epidemiol Biomarkers Prev</source><year>2006</year><volume>15</volume><issue>2</issue><fpage>238</fpage><lpage>244</lpage>
<author><surname>Shoulson</surname> <given-names>I</given-names> </author><author><surname>Glaubiger</surname> <given-names>GA</given-names> </author><author><surname>Chase</surname> <given-names>TN</given-names> </author><title>On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients</title><source>Neurology</source><year>1975</year><volume>25</volume><issue>12</issue><fpage>1144</fpage><lpage>1148</lpage>
<author><surname>Hardie</surname> <given-names>RJ</given-names> </author><author><surname>Lees</surname> <given-names>AJ</given-names> </author><author><surname>Stern</surname> <given-names>GM</given-names> </author><title>On-off fluctuations in Parkinson&#8217;s disease. A clinical and neuropharmacological study</title><source>Brain</source><year>1984</year><volume>107</volume><issue>Pt 2</issue><fpage>487</fpage><lpage>506</lpage>
<author><surname>Bredberg</surname> <given-names>E</given-names> </author><author><surname>Nilsson</surname> <given-names>D</given-names> </author><author><surname>Johansson</surname> <given-names>K</given-names> </author><title>Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson&#8217;s disease</title><source>Eur J Clin Pharmacol</source><year>1993</year><volume>45</volume><issue>2</issue><fpage>117</fpage><lpage>122</lpage>
<author><surname>Sage</surname> <given-names>JI</given-names> </author><author><surname>Schuh</surname> <given-names>L</given-names> </author><author><surname>Heikkila</surname> <given-names>RE</given-names> </author><author><surname>Duvoisin</surname> <given-names>RC</given-names> </author><title>Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson&#8217;s disease</title><source>Clin Neuropharmacol</source><year>1988</year><volume>11</volume><issue>1</issue><fpage>36</fpage><lpage>44</lpage>
<author><surname>Nyholm</surname> <given-names>D</given-names> </author><author><surname>Nilsson Remahl</surname> <given-names>AI</given-names> </author><author><surname>Dizdar</surname> <given-names>N</given-names> </author><title>Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease</title><source>Neurology</source><year>2005</year><volume>64</volume><issue>2</issue><fpage>216</fpage><lpage>223</lpage>
<author><surname>Nilsson</surname> <given-names>D</given-names> </author><author><surname>Nyholm</surname> <given-names>D</given-names> </author><author><surname>Aquilonius</surname> <given-names>SM</given-names> </author><title>Duodenal levodopa infusion in Parkinson&#8217;s disease &#8211; long-term experience</title><source>Acta Neurol Scand</source><year>2001</year><volume>104</volume><issue>6</issue><fpage>343</fpage><lpage>348</lpage>
<author><surname>Devos</surname> <given-names>D</given-names> </author><title>Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson&#8217;s disease</title><source>Mov Disord</source><year>2009</year><volume>24</volume><issue>7</issue><fpage>993</fpage><lpage>1000</lpage>
<author><surname>Nyholm</surname> <given-names>D</given-names> </author><title>Pharmacokinetics of levodopa/carbidopa infusion with and without oral catechol-O-methyl transferase (COMT) inhibitors (DuoCOMT)</title>Available from:
<author><surname>Pekkonen</surname> <given-names>E</given-names> </author><title>Duodenal levodopa infusion, quality of life and autonomic nervous system in Parkinson&#8217;s disease</title>Available from:
<author><surname>Lundqvist</surname> <given-names>C</given-names> </author><author><surname>Beiske</surname> <given-names>A</given-names> </author><title>Continuous delivery of levodopa in patients with advanced idiopathic Parkinsons disease &#8211; cost-benefit</title>Available from:
<author><surname>Nyholm</surname> <given-names>D</given-names> </author><title>Different dyskinesias in Parkinson&#8217;s disease and their relation to levodopa pharmacokinetics (DYSK-PD-2007)</title>Available from:
<author><surname>Kurlan</surname> <given-names>R</given-names> </author><author><surname>Rothfield</surname> <given-names>KP</given-names> </author><author><surname>Woodward</surname> <given-names>WR</given-names> </author><title>Erratic gastric emptying of levodopa may cause &#8220;random&#8221; fluctuations of parkinsonian mobility</title><source>Neurology</source><year>1988</year><volume>38</volume><issue>3</issue><fpage>419</fpage><lpage>421</lpage>
<author><surname>Djaldetti</surname> <given-names>R</given-names> </author><author><surname>Baron</surname> <given-names>J</given-names> </author><author><surname>Ziv</surname> <given-names>I</given-names> </author><author><surname>Melamed</surname> <given-names>E</given-names> </author><title>Gastric emptying in Parkinson&#8217;s disease: patients with and without response fluctuations</title><source>Neurology</source><year>1996</year><volume>46</volume><issue>4</issue><fpage>1051</fpage><lpage>1054</lpage>
<author><surname>Pfeiffer</surname> <given-names>RF</given-names> </author><title>Gastrointestinal dysfunction in Parkinson&#8217;s disease</title><source>Lancet Neurol</source><year>2003</year><volume>2</volume><issue>2</issue><fpage>107</fpage><lpage>116</lpage>
<author><surname>Goetze</surname> <given-names>O</given-names> </author><author><surname>Nikodem</surname> <given-names>AB</given-names> </author><author><surname>Wiezcorek</surname> <given-names>J</given-names> </author><title>Predictors of gastric emptying in Parkinson&#8217;s disease</title><source>Neurogastroenterol Motil</source><year>2006</year><volume>18</volume><issue>5</issue><fpage>369</fpage><lpage>375</lpage>
<author><surname>Steiger</surname> <given-names>MJ</given-names> </author><author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Carta</surname> <given-names>A</given-names> </author><title>The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon &#8220;off &#8221; periods in Parkinson&#8217;s disease</title><source>Clin Neuropharmacol</source><year>1991</year><volume>14</volume><issue>3</issue><fpage>241</fpage><lpage>244</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Fabbri</surname> <given-names>L</given-names> </author><author><surname>Vecsei</surname> <given-names>L</given-names> </author><author><surname>Krygowska-Wajs</surname> <given-names>A</given-names> </author><author><surname>Monici Preti</surname> <given-names>PA</given-names> </author><author><surname>Ruggieri</surname> <given-names>SA</given-names> </author><title>Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease</title><source>Clin Neuropharmacol</source><year>2007</year><volume>30</volume><issue>1</issue><fpage>18</fpage><lpage>24</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Zappia</surname> <given-names>M</given-names> </author><author><surname>Dall&#8217;Armi</surname> <given-names>V</given-names> </author><author><surname>Kulisevsky</surname> <given-names>J</given-names> </author><author><surname>Lamberti</surname> <given-names>P</given-names> </author><author><surname>Obeso</surname> <given-names>JA</given-names> </author><title>Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson&#8217;s disease</title><source>Mov Disord</source><year>2010</year><volume>25</volume><issue>12</issue><fpage>1881</fpage><lpage>1887</lpage>
<author><surname>Chen</surname> <given-names>D</given-names> </author><title>An exploratory study of XP21279 (with Lodosyn&#174;) and Sinemet&#174; in Parkinson&#8217;s disease subjects</title>Available from:
<title>Product candidates, XP21279</title>Available from:
<author><surname>Hsu</surname> <given-names>A</given-names> </author><author><surname>Verhagen Metman</surname> <given-names>L</given-names> </author><author><surname>Ellenbogen</surname> <given-names>A</given-names> </author><title>Comparison of IPX066, a novel extended-release oral carbidopa-levodopa formulation, to immediate-release carbidopa-levodopa in patients with advanced Parkinson&#8217;s disease</title><source>Am Acad Neurol</source><year>2010</year><volume>74</volume><issue>Suppl 2</issue><fpage>A350</fpage>
<title>A study to evaluate the safety and efficacy of IPX066 in subjects with Parkinson&#8217;s disease (APEX-PD)</title>Available from:
<author><surname>Ferr&#233;</surname> <given-names>S</given-names> </author><author><surname>O&#8217;Connor</surname> <given-names>WT</given-names> </author><author><surname>Fuxe</surname> <given-names>K</given-names> </author><author><surname>Ungerstedt</surname> <given-names>U</given-names> </author><title>The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain</title><source>J Neurosci</source><year>1993</year><volume>13</volume><issue>12</issue><fpage>5402</fpage><lpage>5406</lpage>
<author><surname>Svenningsson</surname> <given-names>P</given-names> </author><author><surname>Le Moine</surname> <given-names>C</given-names> </author><author><surname>Aubert</surname> <given-names>I</given-names> </author><author><surname>Burbaud</surname> <given-names>P</given-names> </author><author><surname>Fredholm</surname> <given-names>BB</given-names> </author><author><surname>Bloch</surname> <given-names>B</given-names> </author><title>Cellular distribution of adenosine A2A receptor mRNA in the primate striatum</title><source>J Comp Neurol</source><year>1998</year><volume>399</volume><issue>2</issue><fpage>229</fpage><lpage>240</lpage>
<author><surname>Ferr&#233;</surname> <given-names>S</given-names> </author><author><surname>Fredholm</surname> <given-names>BB</given-names> </author><author><surname>Morelli</surname> <given-names>M</given-names> </author><author><surname>Popoli</surname> <given-names>P</given-names> </author><author><surname>Fuxe</surname> <given-names>K</given-names> </author><title>Adenosine&#8211;dopamine receptor&#8211;receptor interactions as an integrative mechanism in the basal ganglia</title><source>Trends Neurosci</source><year>1997</year><volume>20</volume><issue>10</issue><fpage>482</fpage><lpage>487</lpage>
<author><surname>Mori</surname> <given-names>A</given-names> </author><author><surname>Shindou</surname> <given-names>T</given-names> </author><title>Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists</title><source>Neurology</source><year>2003</year><volume>61</volume><issue>11 Suppl 6</issue><fpage>S44</fpage><lpage>S48</lpage>
<author><surname>Fenu</surname> <given-names>S</given-names> </author><author><surname>Pinna</surname> <given-names>A</given-names> </author><author><surname>Ongini</surname> <given-names>E</given-names> </author><author><surname>Morelli</surname> <given-names>M</given-names> </author><title>Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats</title><source>Eur J Pharmacol</source><year>1997</year><volume>321</volume><issue>2</issue><fpage>143</fpage><lpage>147</lpage>
<author><surname>Rose</surname> <given-names>S</given-names> </author><author><surname>Ramsay Croft</surname> <given-names>N</given-names> </author><author><surname>Jenner</surname> <given-names>P</given-names> </author><title>The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats</title><source>Brain Res</source><year>2007</year><volume>1133</volume><issue>1</issue><fpage>110</fpage><lpage>114</lpage>
<author><surname>Kanda</surname> <given-names>T</given-names> </author><author><surname>Jackson</surname> <given-names>MJ</given-names> </author><author><surname>Smith</surname> <given-names>LA</given-names> </author><title>Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys</title><source>Ann Neurol</source><year>1998</year><volume>43</volume><issue>4</issue><fpage>507</fpage><lpage>513</lpage>
<author><surname>Lundblad</surname> <given-names>M</given-names> </author><author><surname>Vaudano</surname> <given-names>E</given-names> </author><author><surname>Cenci</surname> <given-names>MA</given-names> </author><title>Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia</title><source>J Neurochem</source><year>2003</year><volume>84</volume><issue>6</issue><fpage>1398</fpage><lpage>1410</lpage>
<author><surname>Kanda</surname> <given-names>T</given-names> </author><author><surname>Jackson</surname> <given-names>MJ</given-names> </author><author><surname>Smith</surname> <given-names>LA</given-names> </author><title>Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys</title><source>Exp Neurol</source><year>2000</year><volume>162</volume><issue>2</issue><fpage>321</fpage><lpage>327</lpage>
<author><surname>Bara-Jimenez</surname> <given-names>W</given-names> </author><author><surname>Sherzai</surname> <given-names>A</given-names> </author><author><surname>Dimitrova</surname> <given-names>T</given-names> </author><title>Adenosine A(2A) receptor antagonist treatment of Parkinson&#8217;s disease</title><source>Neurology</source><year>2003</year><volume>61</volume><issue>3</issue><fpage>293</fpage><lpage>296</lpage>
<author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Hubble</surname> <given-names>JP</given-names> </author><author><surname>Truong</surname> <given-names>DD</given-names> </author><title>Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD</title><source>Neurology</source><year>2003</year><volume>61</volume><issue>3</issue><fpage>297</fpage><lpage>303</lpage>
<author><surname>Lewitt</surname> <given-names>PA</given-names> </author><author><surname>Guttman</surname> <given-names>M</given-names> </author><author><surname>Tetrud</surname> <given-names>JW</given-names> </author><title>Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces &#8220;off &#8221; time in Parkinson&#8217;s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)</title><source>Ann Neurol</source><year>2008</year><volume>63</volume><issue>3</issue><fpage>295</fpage><lpage>302</lpage>
<author><surname>Stacy</surname> <given-names>M</given-names> </author><author><surname>Silver</surname> <given-names>D</given-names> </author><author><surname>Mendis</surname> <given-names>T</given-names> </author><title>A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease</title><source>Neurology</source><year>2008</year><volume>70</volume><issue>23</issue><fpage>2233</fpage><lpage>2240</lpage>
<author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Shulman</surname> <given-names>LM</given-names> </author><author><surname>Trugman</surname> <given-names>JM</given-names> </author><title>Study of istradefylline in patients with Parkinson&#8217;s disease on levodopa with motor fluctuations</title><source>Mov Disord</source><year>2008</year><volume>23</volume><issue>15</issue><fpage>2177</fpage><lpage>2185</lpage>
<author><surname>Guttman</surname> <given-names>M</given-names> </author><title>Efficacy of istradefylline in Parkinson&#8217;s disease patients treated with levodopa with motor response complications: primary efficacy results of the KW-6002 US-018 study</title><source>Mov Disord</source><year>2006</year><volume>21</volume><issue>Suppl 15</issue><fpage>S585</fpage>
<title>KW-6002 to treat Parkinson&#8217;s disease. NCT00006337</title>Available from:
<title>2nd generation A2A antagonist</title>Available from:
<title>A phase 2, 12-week, double-blind, dose-finding, placebo-controlled study to assess the efficacy and safety of a range of SCH 420814 doses in subjects with moderate to severe Parkinson&#8217;s disease experiencing motor fluctuations and dyskinesias</title>Available from:
<author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Pourcher</surname> <given-names>E</given-names> </author><author><surname>Micheli</surname> <given-names>F</given-names> </author><title>Efficacy of preladenant, a novel A2A antagonist, as an adjunct to levodopa for the treatment of Parkinson&#8217;s disease</title><source>Presented at Movement Disorder Society&#8217;s 13th International Congress of Parkinson&#8217;s Disease and Movements Disorders</source><other>Paris, France</other><other>7&#8211;11 Jun 2009</other>Abstract Tu-185.
<author><surname>Huyck</surname> <given-names>SB</given-names> </author><author><surname>Wolski</surname> <given-names>K</given-names> </author><author><surname>Cantillon</surname> <given-names>M</given-names> </author><title>Impact of A2A receptor antagonist preladenant on dyskinesia in moderate to severe Parkinson&#8217;s disease: post hoc analysis of dose-finding study</title></other>Presented at Movement Disorder Society&#8217;s 13th International Congress of Parkinson&#8217;s Disease and Movements Disorders</other><other>Paris, France</other><other>7&#8211;11 Jun 2009</other><other>Abstract Tu-187.</other>
<title>A placebo- and active-controlled study of preladenant in early Parkinson&#8216;s disease (study P05664 AM2)</title><other>Available from:</other>
<title>A placebo- and active controlled study of preladenant in subjects with moderate to severe Parkinson&#8216;s disease (study P04938 AM2)</title><other>Available from:</other>
<title>Synosia Therapeutics Pipeline</title><other>Available from:</other>
<title>Sigma-Tau. Research development stages</title><other>Available from:</other>
<author><surname>Ross</surname> <given-names>GW</given-names> </author><author><surname>Abbott</surname> <given-names>RD</given-names> </author><author><surname>Petrovitch</surname> <given-names>H</given-names> </author><title>Association of coffee and caffeine intake with the risk of Parkinson disease</title><source>JAMA</source><year>2000</year><volume>283</volume><issue>20</issue><fpage>2674</fpage><lpage>2679</lpage>
<author><surname>Ascherio</surname> <given-names>A</given-names> </author><author><surname>Zhang</surname> <given-names>SM</given-names> </author><author><surname>Hern&#225;n</surname> <given-names>MA</given-names> </author><title>Prospective study of caffeine consumption and risk of Parkinson&#8217;s disease in men and women</title><source>Ann Neurol</source><year>2001</year><volume>50</volume><issue>1</issue><fpage>56</fpage><lpage>63</lpage>
<author><surname>Tan</surname> <given-names>EK</given-names> </author><author><surname>Tan</surname> <given-names>C</given-names> </author><author><surname>Fook-Chong</surname> <given-names>SM</given-names> </author><title>Dose-dependent protective effect of coffee, tea, and smoking in Parkinson&#8217;s disease: a study in ethnic Chinese</title><source>J Neurol Sci</source><year>2003</year><volume>216</volume><issue>1</issue><fpage>163</fpage><lpage>167</lpage>
<author><surname>Hu</surname> <given-names>G</given-names> </author><author><surname>Bidel</surname> <given-names>S</given-names> </author><author><surname>Jousilahti</surname> <given-names>P</given-names> </author><author><surname>Antikainen</surname> <given-names>R</given-names> </author><author><surname>Tuomilehto</surname> <given-names>J</given-names> </author><title>Coffee and tea consumption and the risk of Parkinson&#8217;s disease</title><source>Mov Disord</source><year>2007</year><volume>22</volume><issue>15</issue><fpage>2242</fpage><lpage>2248</lpage>
<author><surname>Chen</surname> <given-names>JF</given-names> </author><author><surname>Xu</surname> <given-names>K</given-names> </author><author><surname>Petzer</surname> <given-names>JP</given-names> </author><title>Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson&#8217;s disease</title><source>J Neurosci</source><year>2001</year><volume>21</volume><issue>10</issue><fpage>RC143</fpage>
<author><surname>Ikeda</surname> <given-names>K</given-names> </author><author><surname>Kurokawa</surname> <given-names>M</given-names> </author><author><surname>Aoyama</surname> <given-names>S</given-names> </author><author><surname>Kuwana</surname> <given-names>Y</given-names> </author><title>Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson&#8217;s disease</title><source>J Neurochem</source><year>2002</year><volume>80</volume><issue>2</issue><fpage>262</fpage><lpage>270</lpage>
<author><surname>Pierri</surname> <given-names>M</given-names> </author><author><surname>Vaudano</surname> <given-names>E</given-names> </author><author><surname>Sager</surname> <given-names>T</given-names> </author><author><surname>Englund</surname> <given-names>U</given-names> </author><title>KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse</title><source>Neuropharmacology</source><year>2005</year><volume>48</volume><issue>4</issue><fpage>517</fpage><lpage>524</lpage>
<author><surname>Jenner</surname> <given-names>P</given-names> </author><author><surname>Mori</surname> <given-names>A</given-names> </author><author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Morelli</surname> <given-names>M</given-names> </author><author><surname>Fredholm</surname> <given-names>BB</given-names> </author><author><surname>Chen</surname> <given-names>JF</given-names> </author><title>Adenosine, adenosine A2A antagonists, and Parkinson&#8217;s disease</title><source>Parkinsonism Relat Disord</source><year>2009</year><volume>15</volume><issue>6</issue><fpage>406</fpage><lpage>413</lpage>
<author><surname>Blandini</surname> <given-names>F</given-names> </author><author><surname>Armentero</surname> <given-names>MT</given-names> </author><author><surname>Fancellu</surname> <given-names>R</given-names> </author><author><surname>Blaugrund</surname> <given-names>E</given-names> </author><author><surname>Nappi</surname> <given-names>G</given-names> </author><title>Neuroprotective effect of rasagiline in a rodent model of Parkinson&#8217;s disease</title><source>Exp Neurol</source><year>2004</year><volume>187</volume><issue>2</issue><fpage>455</fpage><lpage>459</lpage>
<author><surname>Kupsch</surname> <given-names>A</given-names> </author><author><surname>Sautter</surname> <given-names>J</given-names> </author><author><surname>G&#246;tz</surname> <given-names>ME</given-names> </author><title>Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline</title><source>J Neural Transm</source><year>2001</year><volume>108</volume><issue>8&#8211;9</issue><fpage>985</fpage><lpage>1009</lpage>
<title>A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease</title><source>Arch Neurol</source><year>2004</year><volume>61</volume><issue>4</issue><fpage>561</fpage><lpage>566</lpage>
<author><surname>Olanow</surname> <given-names>CW</given-names> </author><author><surname>Rascol</surname> <given-names>O</given-names> </author><author><surname>Hauser</surname> <given-names>RA</given-names> </author><title>A double-blind, delayed-start trial of rasagiline in Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2009</year><volume>361</volume><issue>13</issue><fpage>1268</fpage><lpage>1278</lpage>
<author><surname>Kieburtz</surname> <given-names>K</given-names> </author><title>ADAGIO misses a beat?</title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><issue>12</issue><fpage>1081</fpage><lpage>1082</lpage>
<author><surname>Ahlskog</surname> <given-names>JE</given-names> </author><author><surname>Uitti</surname> <given-names>RJ</given-names> </author><title>Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?</title><source>Neurology</source><year>2010</year><volume>74</volume><issue>14</issue><fpage>1143</fpage><lpage>1148</lpage>
<author><surname>Marzo</surname> <given-names>A</given-names> </author><author><surname>Dal Bo</surname> <given-names>L</given-names> </author><author><surname>Monti</surname> <given-names>NC</given-names> </author><title>Pharmacokinetics and pharmacodynamics of saf inamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity</title><source>Pharmacol Res</source><year>2004</year><volume>50</volume><issue>1</issue><fpage>77</fpage><lpage>85</lpage>
<author><surname>Caccia</surname> <given-names>C</given-names> </author><author><surname>Maj</surname> <given-names>R</given-names> </author><author><surname>Calabresi</surname> <given-names>M</given-names> </author><title>Safinamide: from molecular targets to a new anti-Parkinson drug</title><source>Neurology</source><year>2006</year><volume>67</volume><issue>7 Suppl 2</issue><fpage>S18</fpage><lpage>S23</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Arnold</surname> <given-names>G</given-names> </author><author><surname>Onofrj</surname> <given-names>M</given-names> </author><title>Improvement of motor function in early Parkinson disease by safinamide</title><source>Neurology</source><year>2004</year><volume>63</volume><issue>4</issue><fpage>746</fpage><lpage>748</lpage>
<author><surname>Borgohain</surname> <given-names>R</given-names> </author><author><surname>Szasz</surname> <given-names>J</given-names> </author><author><surname>Bhatt</surname> <given-names>M</given-names> </author><title>Efficacy and safety of safinamide in patients with Parkinson&#8217;s disease experiencing motor fluctuations: results of a 6-month phase III, randomized, double-blind, placebo-controlled study</title><year>2009</year>Available from:
<author><surname>Willmer</surname> <given-names>J</given-names> </author><title>Safinamide in levodopa induced dyskinesia in Parkinson&#8217;s disease subjects (safinamide-LID)</title>Available from:
<author><surname>Schapira</surname> <given-names>AH</given-names> </author><title>Safinamide in the treatment of Parkinson&#8217;s disease</title><source>Expert Opin Pharmacother</source><year>2010</year><volume>11</volume><issue>13</issue><fpage>2261</fpage><lpage>2268</lpage>
<author><surname>Stacy</surname> <given-names>M</given-names> </author><author><surname>Galbreath</surname> <given-names>A</given-names> </author><title>Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia</title><source>Clin Neuropharmacol</source><year>2008</year><volume>31</volume><issue>1</issue><fpage>51</fpage><lpage>56</lpage>
<author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Rascol</surname> <given-names>O</given-names> </author><author><surname>Korczyn</surname> <given-names>AD</given-names> </author><title>Ten-year follow-up of Parkinson&#8217;s disease patients randomized to initial therapy with ropinirole or levodopa</title><source>Mov Disord</source><year>2007</year><volume>22</volume><issue>16</issue><fpage>2409</fpage><lpage>2417</lpage>
<author><surname>Holloway</surname> <given-names>R</given-names> </author><author><surname>Marek</surname> <given-names>K</given-names> </author><author><surname>Biglan</surname> <given-names>K</given-names> </author><title>Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease</title><source>Arch Neurol</source><year>2009</year><volume>66</volume><issue>5</issue><fpage>563</fpage><lpage>570</lpage>
<title>Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression</title><source>JAMA</source><year>2002</year><volume>287</volume><issue>13</issue><fpage>1653</fpage><lpage>1661</lpage>
<author><surname>Whone</surname> <given-names>AL</given-names> </author><author><surname>Watts</surname> <given-names>RL</given-names> </author><author><surname>Stoessl</surname> <given-names>AJ</given-names> </author><title>Slower progression of Parkinson&#8217;s disease with ropinirole versus levodopa: the REAL-PET study</title><source>Ann Neurol</source><year>2003</year><volume>54</volume><issue>1</issue><fpage>93</fpage><lpage>101</lpage>
<author><surname>Schapira</surname> <given-names>AH</given-names> </author><author><surname>Albrecht</surname> <given-names>S</given-names> </author><author><surname>Barone</surname> <given-names>P</given-names> </author><title>Immediate vs delayed-start pramipexole in early Parkinson&#8217;s disease: the PROUD study</title><source>Parkinsonism Relat Disord</source><year>2009</year><volume>15</volume><issue>Suppl 2</issue><fpage>S81</fpage>
<author><surname>Schapira</surname> <given-names>AH</given-names> </author><author><surname>Albrecht</surname> <given-names>S</given-names> </author><author><surname>Barone</surname> <given-names>P</given-names> </author><title>Rationale for delayed-start study of pramipexole in Parkinson&#8217;s disease: the PROUD study</title><source>Mov Disord</source><year>2010</year><volume>25</volume><issue>11</issue><fpage>1627</fpage><lpage>1632</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Hersh</surname> <given-names>BP</given-names> </author><author><surname>Scott</surname> <given-names>BL</given-names> </author><author><surname>Nausieda</surname> <given-names>PA</given-names> </author><author><surname>Giorgi</surname> <given-names>L</given-names> </author><title>Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson&#8217;s disease: a randomized, double-blind, non-inferiority crossover study</title><source>Curr Med Res Opin</source><year>2008</year><volume>24</volume><issue>10</issue><fpage>2883</fpage><lpage>2895</lpage>
<author><surname>Pahwa</surname> <given-names>R</given-names> </author><author><surname>Stacy</surname> <given-names>MA</given-names> </author><author><surname>Factor</surname> <given-names>SA</given-names> </author><title>Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease</title><source>Neurology</source><year>2007</year><volume>68</volume><issue>14</issue><fpage>1108</fpage><lpage>1115</lpage>
<author><surname>Hersh</surname> <given-names>BP</given-names> </author><author><surname>Earl</surname> <given-names>NL</given-names> </author><author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Stacy</surname> <given-names>M</given-names> </author><title>Early treatment benefits of ropinirole prolonged release in Parkinson&#8217;s disease patients with motor fluctuations</title><source>Mov Disord</source><year>2010</year><volume>25</volume><issue>7</issue><fpage>927</fpage><lpage>931</lpage>
<author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Schapira</surname> <given-names>AH</given-names> </author><author><surname>Rascol</surname> <given-names>O</given-names> </author><title>Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson&#8217;s disease</title><source>Mov Disord</source><year>2010</year><volume>25</volume><issue>15</issue><fpage>2542</fpage><lpage>2549</lpage>
<author><surname>Driver-Dunckley</surname> <given-names>E</given-names> </author><author><surname>Samanta</surname> <given-names>J</given-names> </author><author><surname>Stacy</surname> <given-names>M</given-names> </author><title>Pathological gambling associated with dopamine agonist therapy in Parkinson&#8217;s disease</title><source>Neurology</source><year>2003</year><volume>61</volume><issue>3</issue><fpage>422</fpage><lpage>423</lpage>
<author><surname>Weintraub</surname> <given-names>D</given-names> </author><author><surname>Siderowf</surname> <given-names>AD</given-names> </author><author><surname>Potenza</surname> <given-names>MN</given-names> </author><title>Association of dopamine agonist use with impulse control disorders in Parkinson disease</title><source>Arch Neurol</source><year>2006</year><volume>63</volume><issue>7</issue><fpage>969</fpage><lpage>973</lpage>
<author><surname>Voon</surname> <given-names>V</given-names> </author><author><surname>Hassan</surname> <given-names>K</given-names> </author><author><surname>Zurowski</surname> <given-names>M</given-names> </author><title>Prevalence of repetitive and reward-seeking behaviors in Parkinson disease</title><source>Neurology</source><year>2006</year><volume>67</volume><issue>7</issue><fpage>1254</fpage><lpage>1257</lpage>
<author><surname>Evans</surname> <given-names>AH</given-names> </author><author><surname>Strafella</surname> <given-names>AP</given-names> </author><author><surname>Weintraub</surname> <given-names>D</given-names> </author><author><surname>Stacy</surname> <given-names>M</given-names> </author><title>Impulsive and compulsive behaviors in Parkinson&#8217;s disease</title><source>Mov Disord</source><year>2009</year><volume>24</volume><issue>11</issue><fpage>1561</fpage><lpage>1570</lpage>
<author><surname>Weintraub</surname> <given-names>D</given-names> </author><author><surname>Koester</surname> <given-names>J</given-names> </author><author><surname>Potenza</surname> <given-names>MN</given-names> </author><title>Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients</title><source>Arch Neurol</source><year>2010</year><volume>67</volume><issue>5</issue><fpage>589</fpage><lpage>595</lpage>
<author><surname>Thomas</surname> <given-names>A</given-names> </author><author><surname>Bonanni</surname> <given-names>L</given-names> </author><author><surname>Gambi</surname> <given-names>F</given-names> </author><author><surname>di Iorio</surname> <given-names>A</given-names> </author><author><surname>Onofrj</surname> <given-names>M</given-names> </author><title>Pathological gambling in Parkinson disease is reduced by amantadine</title><source>Ann Neurol</source><year>2010</year><volume>68</volume><issue>3</issue><fpage>400</fpage><lpage>404</lpage>
<author><surname>Weintraub</surname> <given-names>D</given-names> </author><author><surname>Sohr</surname> <given-names>M</given-names> </author><author><surname>Potenza</surname> <given-names>MN</given-names> </author><title>Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study</title><source>Ann Neurol</source><year>2010</year><volume>68</volume><issue>6</issue><fpage>963</fpage><lpage>968</lpage>
<author><surname>Weintraub</surname> <given-names>D</given-names> </author><title>Naltrexone for impulse control disorders in Parkinson&#8216;s disease</title>Available from:
<author><surname>Modi</surname> <given-names>G</given-names> </author><author><surname>Pillay</surname> <given-names>V</given-names> </author><author><surname>Choonara</surname> <given-names>YE</given-names> </author><title>Advances in the treatment of neurodegenerative disorders employing nanotechnology</title><source>Ann N Y Acad Sci</source><year>2010</year><volume>1184</volume><fpage>154</fpage><lpage>172</lpage>
<author><surname>Modi</surname> <given-names>G</given-names> </author><author><surname>Pillay</surname> <given-names>V</given-names> </author><author><surname>Choonara</surname> <given-names>YE</given-names> </author><author><surname>Ndesendo</surname> <given-names>VM</given-names> </author><author><surname>du Toit</surname> <given-names>LC</given-names> </author><author><surname>Naidoo</surname> <given-names>D</given-names> </author><title>Nanotechnological applications for the treatment of neurodegenerative disorders</title><source>Prog Neurobiol</source><year>2009</year><volume>88</volume><issue>4</issue><fpage>272</fpage><lpage>285</lpage>
<author><surname>Staples</surname> <given-names>M</given-names> </author><title>Microchips and controlled-release drug reservoirs</title><source>Wiley Interdiscip Rev Nanomed Nanobiotechnol</source><year>2010</year><volume>2</volume><issue>4</issue><fpage>400</fpage><lpage>417</lpage>
<author><surname>Linazasoro</surname> <given-names>G</given-names> </author><title>Potential applications of nanotechnologies to Parkinson&#8217;s disease therapy</title><source>Parkinsonism Relat Disord</source><year>2008</year><volume>14</volume><issue>5</issue><fpage>383</fpage><lpage>392</lpage>
<author><surname>Bergman</surname> <given-names>H</given-names> </author><author><surname>Wichmann</surname> <given-names>T</given-names> </author><author><surname>DeLong</surname> <given-names>MR</given-names> </author><title>Reversal of experimental parkinsonism by lesions of the subthalamic nucleus</title><source>Science</source><year>1990</year><volume>249</volume><issue>4975</issue><fpage>1436</fpage><lpage>1438</lpage>
<author><surname>Aziz</surname> <given-names>TZ</given-names> </author><author><surname>Peggs</surname> <given-names>D</given-names> </author><author><surname>Sambrook</surname> <given-names>MA</given-names> </author><author><surname>Crossman</surname> <given-names>AR</given-names> </author><title>Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate</title><source>Mov Disord</source><year>1991</year><volume>6</volume><issue>4</issue><fpage>288</fpage><lpage>292</lpage>
<author><surname>Benazzouz</surname> <given-names>A</given-names> </author><author><surname>Gross</surname> <given-names>C</given-names> </author><author><surname>F&#233;ger</surname> <given-names>J</given-names> </author><author><surname>Boraud</surname> <given-names>T</given-names> </author><author><surname>Bioulac</surname> <given-names>B</given-names> </author><title>Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys</title><source>Eur J Neurosci</source><year>1993</year><volume>5</volume><issue>4</issue><fpage>382</fpage><lpage>389</lpage>
<author><surname>Wichmann</surname> <given-names>T</given-names> </author><author><surname>Bergman</surname> <given-names>H</given-names> </author><author><surname>DeLong</surname> <given-names>MR</given-names> </author><title>The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism</title><source>J Neurophysiol</source><year>1994</year><volume>72</volume><issue>2</issue><fpage>521</fpage><lpage>530</lpage>
<author><surname>Kleiner-Fisman</surname> <given-names>G</given-names> </author><author><surname>Fisman</surname> <given-names>DN</given-names> </author><author><surname>Sime</surname> <given-names>E</given-names> </author><author><surname>Saint-Cyr</surname> <given-names>JA</given-names> </author><author><surname>Lozano</surname> <given-names>AM</given-names> </author><author><surname>Lang</surname> <given-names>AE</given-names> </author><title>Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease</title><source>J Neurosurg</source><year>2003</year><volume>99</volume><issue>3</issue><fpage>489</fpage><lpage>495</lpage>
<author><surname>Weaver</surname> <given-names>FM</given-names> </author><author><surname>Follett</surname> <given-names>K</given-names> </author><author><surname>Stern</surname> <given-names>M</given-names> </author><title>Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial</title><source>JAMA</source><year>2009</year><volume>301</volume><issue>1</issue><fpage>63</fpage><lpage>73</lpage>
<author><surname>Follett</surname> <given-names>KA</given-names> </author><author><surname>Weaver</surname> <given-names>FM</given-names> </author><author><surname>Stern</surname> <given-names>M</given-names> </author><title>Pallidal versus subthalamic deep-brain stimulation for Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>22</issue><fpage>2077</fpage><lpage>2091</lpage>
<author><surname>Mazzone</surname> <given-names>P</given-names> </author><author><surname>Lozano</surname> <given-names>A</given-names> </author><author><surname>Stanzione</surname> <given-names>P</given-names> </author><title>Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson&#8217;s disease</title><source>Neuroreport</source><year>2005</year><volume>16</volume><issue>17</issue><fpage>1877</fpage><lpage>1881</lpage>
<author><surname>Plaha</surname> <given-names>P</given-names> </author><author><surname>Gill</surname> <given-names>SS</given-names> </author><title>Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson&#8217;s disease</title><source>Neuroreport</source><year>2005</year><volume>16</volume><issue>17</issue><fpage>1883</fpage><lpage>1887</lpage>
<author><surname>Moro</surname> <given-names>E</given-names> </author><author><surname>Hamani</surname> <given-names>C</given-names> </author><author><surname>Poon</surname> <given-names>YY</given-names> </author><title>Unilateral pedunculopontine stimulation improves falls in Parkinson&#8217;s disease</title><source>Brain</source><year>2010</year><volume>133</volume><issue>Pt 1</issue><fpage>215</fpage><lpage>224</lpage>
<author><surname>Ferraye</surname> <given-names>MU</given-names> </author><author><surname>Deb&#251;</surname> <given-names>B</given-names> </author><author><surname>Fraix</surname> <given-names>V</given-names> </author><title>Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson&#8216;s disease</title><source>Brain</source><year>2010</year><volume>133</volume><issue>Pt 1</issue><fpage>205</fpage><lpage>214</lpage>
<author><surname>Benabid</surname> <given-names>AL</given-names> </author><author><surname>Chabardes</surname> <given-names>S</given-names> </author><author><surname>Mitrofanis</surname> <given-names>J</given-names> </author><author><surname>Pollak</surname> <given-names>P</given-names> </author><title>Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson&#8217;s disease</title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><issue>1</issue><fpage>67</fpage><lpage>81</lpage>
<author><surname>Benabid</surname> <given-names>AL</given-names> </author><author><surname>Pollak</surname> <given-names>P</given-names> </author><author><surname>Gao</surname> <given-names>D</given-names> </author><title>Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders</title><source>J Neurosurg</source><year>1996</year><volume>84</volume><issue>2</issue><fpage>203</fpage><lpage>214</lpage>
<author><surname>Meissner</surname> <given-names>W</given-names> </author><author><surname>Leblois</surname> <given-names>A</given-names> </author><author><surname>Hansel</surname> <given-names>D</given-names> </author><title>Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations</title><source>Brain</source><year>2005</year><volume>128</volume><issue>Pt 10</issue><fpage>2372</fpage><lpage>2382</lpage>
<author><surname>Welter</surname> <given-names>ML</given-names> </author><author><surname>Houeto</surname> <given-names>JL</given-names> </author><author><surname>Bonnet</surname> <given-names>AM</given-names> </author><title>Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients</title><source>Arch Neurol</source><year>2004</year><volume>61</volume><issue>1</issue><fpage>89</fpage><lpage>96</lpage>
<author><surname>Xia</surname> <given-names>R</given-names> </author><author><surname>Berger</surname> <given-names>F</given-names> </author><author><surname>Piallat</surname> <given-names>B</given-names> </author><author><surname>Benabid</surname> <given-names>AL</given-names> </author><title>Alteration of hormone and neurotransmitter production in cultured cells by high and low frequency electrical stimulation</title><source>Acta Neurochir (Wien)</source><year>2007</year><volume>149</volume><issue>1</issue><fpage>67</fpage><lpage>73</lpage>
<author><surname>Harnack</surname> <given-names>D</given-names> </author><author><surname>Meissner</surname> <given-names>W</given-names> </author><author><surname>Jira</surname> <given-names>JA</given-names> </author><author><surname>Winter</surname> <given-names>C</given-names> </author><author><surname>Morgenstern</surname> <given-names>R</given-names> </author><author><surname>Kupsch</surname> <given-names>A</given-names> </author><title>Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism</title><source>Exp Neurol</source><year>2008</year><volume>210</volume><issue>1</issue><fpage>257</fpage><lpage>260</lpage>
<author><surname>Maesawa</surname> <given-names>S</given-names> </author><author><surname>Kaneoke</surname> <given-names>Y</given-names> </author><author><surname>Kajita</surname> <given-names>Y</given-names> </author><title>Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons</title><source>J Neurosurg</source><year>2004</year><volume>100</volume><issue>4</issue><fpage>679</fpage><lpage>687</lpage>
<author><surname>Temel</surname> <given-names>Y</given-names> </author><author><surname>Visser-Vandewalle</surname> <given-names>V</given-names> </author><author><surname>Kaplan</surname> <given-names>S</given-names> </author><title>Protection of nigral cell death by bilateral subthalamic nucleus stimulation</title><source>Brain Res</source><year>2006</year><volume>1120</volume><issue>1</issue><fpage>100</fpage><lpage>105</lpage>
<author><surname>Wallace</surname> <given-names>BA</given-names> </author><author><surname>Ashkan</surname> <given-names>K</given-names> </author><author><surname>Heise</surname> <given-names>CE</given-names> </author><title>Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys</title><source>Brain</source><year>2007</year><volume>130</volume><issue>Pt 8</issue><fpage>2129</fpage><lpage>2145</lpage>
<author><surname>Spieles-Engemann</surname> <given-names>AL</given-names> </author><author><surname>Behbehani</surname> <given-names>MM</given-names> </author><author><surname>Collier</surname> <given-names>TJ</given-names> </author><title>Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss</title><source>Neurobiol Dis</source><year>2010</year><volume>39</volume><issue>1</issue><fpage>105</fpage><lpage>115</lpage>
<author><surname>Bergman</surname> <given-names>H</given-names> </author><author><surname>Wichmann</surname> <given-names>T</given-names> </author><author><surname>Karmon</surname> <given-names>B</given-names> </author><author><surname>DeLong</surname> <given-names>MR</given-names> </author><title>The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism</title><source>J Neurophysiol</source><year>1994</year><volume>72</volume><issue>2</issue><fpage>507</fpage><lpage>520</lpage>
<author><surname>Crossman</surname> <given-names>AR</given-names> </author><author><surname>Mitchell</surname> <given-names>IJ</given-names> </author><author><surname>Sambrook</surname> <given-names>MA</given-names> </author><title>Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey</title><source>Neuropharmacology</source><year>1985</year><volume>24</volume><issue>6</issue><fpage>587</fpage><lpage>591</lpage>
<author><surname>Eidelberg</surname> <given-names>D</given-names> </author><author><surname>Moeller</surname> <given-names>JR</given-names> </author><author><surname>Dhawan</surname> <given-names>V</given-names> </author><title>The metabolic topography of parkinsonism</title><source>J Cereb Blood Flow Metab</source><year>1994</year><volume>14</volume><issue>5</issue><fpage>783</fpage><lpage>801</lpage>
<title>Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>13</issue><fpage>956</fpage><lpage>963</lpage>
<author><surname>Charles</surname> <given-names>PD</given-names> </author><author><surname>van Blercom</surname> <given-names>N</given-names> </author><author><surname>Krack</surname> <given-names>P</given-names> </author><title>Predictors of effective bilateral subthalamic nucleus stimulation for PD</title><source>Neurology</source><year>2002</year><volume>59</volume><issue>6</issue><fpage>932</fpage><lpage>934</lpage>
<author><surname>Deuschl</surname> <given-names>G</given-names> </author><author><surname>Schade-Brittinger</surname> <given-names>C</given-names> </author><author><surname>Krack</surname> <given-names>P</given-names> </author><title>A randomized trial of deep-brain stimulation for Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2006</year><volume>355</volume><issue>9</issue><fpage>896</fpage><lpage>908</lpage>
<author><surname>Volkmann</surname> <given-names>J</given-names> </author><title>Deep brain stimulation for the treatment of Parkinson&#8217;s disease</title><source>J Clin Neurophysiol</source><year>2004</year><volume>21</volume><issue>1</issue><fpage>6</fpage><lpage>17</lpage>
<author><surname>Morgante</surname> <given-names>L</given-names> </author><author><surname>Morgante</surname> <given-names>F</given-names> </author><author><surname>Moro</surname> <given-names>E</given-names> </author><title>How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire</title><source>Parkinsonism Relat Disord</source><year>2007</year><volume>13</volume><issue>8</issue><fpage>528</fpage><lpage>531</lpage>
<author><surname>Espay</surname> <given-names>AJ</given-names> </author><author><surname>Vaughan</surname> <given-names>JE</given-names> </author><author><surname>Marras</surname> <given-names>C</given-names> </author><author><surname>Fowler</surname> <given-names>R</given-names> </author><author><surname>Eckman</surname> <given-names>MH</given-names> </author><title>Early versus delayed bilateral subthalamic deep brain stimulation for parkinson&#8217;s disease: a decision analysis</title><source>Mov Disord</source><year>2010</year><volume>25</volume><issue>10</issue><fpage>1456</fpage><lpage>1463</lpage>
<author><surname>Deuschl</surname> <given-names>G</given-names> </author><title>Controlled trial of deep brain stimulation in early patients with Parkinson&#8217;s disease</title>Available from:
<author><surname>Charles</surname> <given-names>PD</given-names> </author><title>Deep brain stimulation (DBS) for early stage Parkinson&#8217;s disease (PD)</title>Available from:
<author><surname>Keeler</surname> <given-names>CE</given-names> </author><title>Gene therapy</title><source>J Hered</source><year>1947</year><volume>38</volume><issue>10</issue><fpage>294</fpage><lpage>298</lpage>
<author><surname>Morrow</surname> <given-names>JF</given-names> </author><title>The prospects for gene therapy in humans</title><source>Ann N Y Acad Sci</source><year>1976</year><volume>265</volume><fpage>13</fpage><lpage>21</lpage>
<author><surname>Nagatsu</surname> <given-names>T</given-names> </author><author><surname>Sawada</surname> <given-names>M</given-names> </author><title>Biochemistry of postmortem brains in Parkinson&#8217;s disease: historical overview and future prospects</title><source>J Neural Transm Suppl</source><year>2007</year><issue>72</issue><fpage>113</fpage><lpage>120</lpage>
<author><surname>Bankiewicz</surname> <given-names>KS</given-names> </author><author><surname>Forsayeth</surname> <given-names>J</given-names> </author><author><surname>Eberling</surname> <given-names>JL</given-names> </author><title>Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC</title><source>Mol Ther</source><year>2006</year><volume>14</volume><issue>4</issue><fpage>564</fpage><lpage>570</lpage>
<author><surname>Shen</surname> <given-names>Y</given-names> </author><author><surname>Muramatsu</surname> <given-names>S</given-names> </author><author><surname>Ikeguchi</surname> <given-names>K</given-names> </author><title>Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson&#8217;s disease</title><source>Hum Gene Ther</source><year>2000</year><volume>11</volume><issue>11</issue><fpage>1509</fpage><lpage>1519</lpage>
<author><surname>Muramatsu</surname> <given-names>S</given-names> </author><author><surname>Fujimoto</surname> <given-names>K</given-names> </author><author><surname>Ikeguchi</surname> <given-names>K</given-names> </author><title>Behavioral recovery in a primate model of Parkinson&#8217;s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes</title><source>Hum Gene Ther</source><year>2002</year><volume>13</volume><issue>3</issue><fpage>345</fpage><lpage>354</lpage>
<author><surname>Jarraya</surname> <given-names>B</given-names> </author><author><surname>Boulet</surname> <given-names>S</given-names> </author><author><surname>Ralph</surname> <given-names>GS</given-names> </author><title>Dopamine gene therapy for Parkinson&#8217;s disease in a nonhuman primate without associated dyskinesia</title><source>Sci Transl Med</source><year>2009</year><volume>1</volume><issue>2</issue><fpage>2ra4</fpage>
<title>Oxford BioMedica announces two-year phase I/II results of ProSavin&#174; in Parkinson&#8217;s disease &#8211; 6/14/2010</title>Available from:
<author><surname>Palfi</surname> <given-names>S</given-names> </author><title>Phase I/II study of the safety, efficacy and dose evaluation of ProSavin for the treatment of bilateral idiopathic Parkinson&#8217;s disease</title>Available from:
<author><surname>Bankiewicz</surname> <given-names>KS</given-names> </author><author><surname>Eberling</surname> <given-names>JL</given-names> </author><author><surname>Kohutnicka</surname> <given-names>M</given-names> </author><title>Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach</title><source>Exp Neurol</source><year>2000</year><volume>164</volume><issue>1</issue><fpage>2</fpage><lpage>14</lpage>
<author><surname>Eberling</surname> <given-names>JL</given-names> </author><author><surname>Jagust</surname> <given-names>WJ</given-names> </author><author><surname>Christine</surname> <given-names>CW</given-names> </author><title>Results from a phase I safety trial of hAADC gene therapy for Parkinson disease</title><source>Neurology</source><year>2008</year><volume>70</volume><issue>21</issue><fpage>1980</fpage><lpage>1983</lpage>
<author><surname>Muramatsu</surname> <given-names>S</given-names> </author><author><surname>Fujimoto</surname> <given-names>K</given-names> </author><author><surname>Kato</surname> <given-names>S</given-names> </author><title>A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson&#8217;s disease</title><source>Mol Ther</source><year>2010</year><volume>18</volume><issue>9</issue><fpage>1731</fpage><lpage>1735</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Ruggieri</surname> <given-names>S</given-names> </author><author><surname>Vacca</surname> <given-names>L</given-names> </author><author><surname>Olanow</surname> <given-names>CW</given-names> </author><title>Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson&#8217;s disease</title><source>Brain</source><year>2002</year><volume>125</volume><issue>Pt 9</issue><fpage>2058</fpage><lpage>2066</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><author><surname>Obeso</surname> <given-names>JA</given-names> </author><author><surname>Stocchi</surname> <given-names>F</given-names> </author><title>Continuous dopamine-receptor stimulation in advanced Parkinson&#8217;s disease</title><source>Trends Neurosci</source><year>2000</year><volume>23</volume><issue>10 Suppl</issue><fpage>S109</fpage><lpage>S115</lpage>
<author><surname>Chase</surname> <given-names>TN</given-names> </author><title>Levodopa therapy: consequences of the nonphysiologic replacement of dopamine</title><source>Neurology</source><year>1998</year><volume>50</volume><issue>5 Suppl 5</issue><fpage>S17</fpage><lpage>S25</lpage>
<author><surname>Carlsson</surname> <given-names>T</given-names> </author><author><surname>Winkler</surname> <given-names>C</given-names> </author><author><surname>Burger</surname> <given-names>C</given-names> </author><title>Reversal of dyskinesias in an animal model of Parkinson&#8217;s disease by continuous L-DOPA delivery using rAAV vectors</title><source>Brain</source><year>2005</year><volume>128</volume><issue>Pt 3</issue><fpage>559</fpage><lpage>569</lpage>
<author><surname>Kaplitt</surname> <given-names>MG</given-names> </author><author><surname>Feigin</surname> <given-names>A</given-names> </author><author><surname>Tang</surname> <given-names>C</given-names> </author><title>Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson&#8217;s disease: an open label, phase I trial</title><source>Lancet</source><year>2007</year><volume>369</volume><issue>9579</issue><fpage>2097</fpage><lpage>2105</lpage>
<author><surname>Stoessl</surname> <given-names>AJ</given-names> </author><title>Gene therapy for Parkinson&#8217;s disease: early data</title><source>Lancet</source><year>2007</year><volume>369</volume><issue>9579</issue><fpage>2056</fpage><lpage>2058</lpage>
<author><surname>Schapira</surname> <given-names>AH</given-names> </author><author><surname>Olanow</surname> <given-names>CW</given-names> </author><title>Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions</title><source>JAMA</source><year>2004</year><volume>291</volume><issue>3</issue><fpage>358</fpage><lpage>364</lpage>
<author><surname>Lin</surname> <given-names>LF</given-names> </author><author><surname>Doherty</surname> <given-names>DH</given-names> </author><author><surname>Lile</surname> <given-names>JD</given-names> </author><author><surname>Bektesh</surname> <given-names>S</given-names> </author><author><surname>Collins</surname> <given-names>F</given-names> </author><title>GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons</title><source>Science</source><year>1993</year><volume>260</volume><issue>5111</issue><fpage>1130</fpage><lpage>1132</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><author><surname>Burchiel</surname> <given-names>KJ</given-names> </author><author><surname>Comella</surname> <given-names>CL</given-names> </author><title>Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD</title><source>Neurology</source><year>2003</year><volume>60</volume><issue>1</issue><fpage>69</fpage><lpage>73</lpage>
<author><surname>Kordower</surname> <given-names>JH</given-names> </author><author><surname>Palfi</surname> <given-names>S</given-names> </author><author><surname>Chen</surname> <given-names>EY</given-names> </author><title>Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson&#8217;s disease</title><source>Ann Neurol</source><year>1999</year><volume>46</volume><issue>3</issue><fpage>419</fpage><lpage>424</lpage>
<author><surname>Kirik</surname> <given-names>D</given-names> </author><author><surname>Rosenblad</surname> <given-names>C</given-names> </author><author><surname>Bjorklund</surname> <given-names>A</given-names> </author><author><surname>Mandel</surname> <given-names>RJ</given-names> </author><title>Long-term rAA V-mediated gene transfer of GDNF in the rat Parkinson&#8217;s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system</title><source>J Neurosci</source><year>2000</year><volume>20</volume><issue>12</issue><fpage>4686</fpage><lpage>4700</lpage>
<author><surname>Wang</surname> <given-names>L</given-names> </author><author><surname>Muramatsu</surname> <given-names>S</given-names> </author><author><surname>Lu</surname> <given-names>Y</given-names> </author><title>Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson&#8217;s disease</title><source>Gene Ther</source><year>2002</year><volume>9</volume><issue>6</issue><fpage>381</fpage><lpage>389</lpage>
<author><surname>Kordower</surname> <given-names>JH</given-names> </author><author><surname>Emborg</surname> <given-names>ME</given-names> </author><author><surname>Bloch</surname> <given-names>J</given-names> </author><title>Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson&#8217;s disease</title><source>Science</source><year>2000</year><volume>290</volume><issue>5492</issue><fpage>767</fpage><lpage>773</lpage>
<author><surname>Lo Bianco</surname> <given-names>C</given-names> </author><author><surname>D&#233;glon</surname> <given-names>N</given-names> </author><author><surname>Pralong</surname> <given-names>W</given-names> </author><author><surname>Aebischer</surname> <given-names>P</given-names> </author><title>Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson&#8217;s disease</title><source>Neurobiol Dis</source><year>2004</year><volume>17</volume><issue>2</issue><fpage>283</fpage><lpage>289</lpage>
<author><surname>Gill</surname> <given-names>SS</given-names> </author><author><surname>Patel</surname> <given-names>NK</given-names> </author><author><surname>Hotton</surname> <given-names>GR</given-names> </author><title>Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease</title><source>Nat Med</source><year>2003</year><volume>9</volume><issue>5</issue><fpage>589</fpage><lpage>595</lpage>
<author><surname>Patel</surname> <given-names>NK</given-names> </author><author><surname>Bunnage</surname> <given-names>M</given-names> </author><author><surname>Plaha</surname> <given-names>P</given-names> </author><author><surname>Svendsen</surname> <given-names>CN</given-names> </author><author><surname>Heywood</surname> <given-names>P</given-names> </author><author><surname>Gill</surname> <given-names>SS</given-names> </author><title>Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study</title><source>Ann Neurol</source><year>2005</year><volume>57</volume><issue>2</issue><fpage>298</fpage><lpage>302</lpage>
<author><surname>Lang</surname> <given-names>AE</given-names> </author><author><surname>Gill</surname> <given-names>S</given-names> </author><author><surname>Patel</surname> <given-names>NK</given-names> </author><title>Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease [Erratum in: Ann Neurol. 2006;60(6):747]</title><source>Ann Neurol</source><year>2006</year><volume>59</volume><issue>3</issue><fpage>459</fpage><lpage>466</lpage>
<author><surname>Gasmi</surname> <given-names>M</given-names> </author><author><surname>Herzog</surname> <given-names>CD</given-names> </author><author><surname>Brandon</surname> <given-names>EP</given-names> </author><title>Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson&#8217;s disease</title><source>Mol Ther</source><year>2007</year><volume>15</volume><issue>1</issue><fpage>62</fpage><lpage>68</lpage>
<author><surname>Gasmi</surname> <given-names>M</given-names> </author><author><surname>Brandon</surname> <given-names>EP</given-names> </author><author><surname>Herzog</surname> <given-names>CD</given-names> </author><title>AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson&#8217;s disease</title><source>Neurobiol Dis</source><year>2007</year><volume>27</volume><issue>1</issue><fpage>67</fpage><lpage>76</lpage>
<author><surname>Kordower</surname> <given-names>JH</given-names> </author><author><surname>Herzog</surname> <given-names>CD</given-names> </author><author><surname>Dass</surname> <given-names>B</given-names> </author><title>Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys</title><source>Ann Neurol</source><year>2006</year><volume>60</volume><issue>6</issue><fpage>706</fpage><lpage>715</lpage>
<author><surname>Marks</surname> <given-names>WJ</given-names> <suffix>Jr</suffix> </author><author><surname>Ostrem</surname> <given-names>JL</given-names> </author><author><surname>Verhagen</surname> <given-names>L</given-names> </author><title>Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson&#8217;s disease: an open-label, phase I trial</title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><issue>5</issue><fpage>400</fpage><lpage>408</lpage>
<author><surname>Siffert</surname> <given-names>J</given-names> </author><title>Double-blind, multicenter, sham surgery controlled study of CERE-120 in subjects with idiopathic Parkinson&#8217;s disease</title>Available from:
<author><surname>Klejbor</surname> <given-names>I</given-names> </author><author><surname>Stachowiak</surname> <given-names>EK</given-names> </author><author><surname>Bharali</surname> <given-names>DJ</given-names> </author><title>ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology</title><source>J Neurosci Methods</source><year>2007</year><volume>165</volume><issue>2</issue><fpage>230</fpage><lpage>243</lpage>
<author><surname>Parkinson</surname> <given-names>J</given-names> </author><source>An Essay on the Shaking Palsy</source><other>London</other><publisher>Sherwood, Neely and Jones</publisher><year>1817</year>